Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Psychedelic profiles: psilocybin; Awakn releases data from Phase II study for alcohol use disorder; Canada amends Special Access Program for psychedelic medicines.
Gwella on making microdosing mainstream; The MHRA releases new guidance on using data in clinical trials; Psychedelics: the newest tool in nuclear negotiations?
Healthcare professionals’ perception of psychedelic medicines; Australian regulator refuses to reclassify psychedelic compounds; COMPASS shares further data from COMP360 Phase IIb trial
Is the NHS ready to embrace psychedelics as medicine?; DEA again boosts 2022 production goals for psychedelic medicines; MAPS and Vine Ventures raise US$70m through revenue sharing model
Has psychedelic research reached a tipping point?; Psychedelics can change humanity for the better; Seelos Therapeutics raises US$20m in private placement
Enhancing the accessibility of psychedelic healthcare; MDMA and psychotherapy in combination could be used to treat alcoholism; Psychedelic therapy is poised to revolutionise mental health. Can VR accelerate it?
Inside the UK’s campaign to reschedule psilocybin with MP Crispin Blunt; Awakn signs MOU with the NHS to increase accessibility of psychedelic medicines; DEA once again boosts psilocybin, MDMA and DMT production quotas
Psychedelic Healthcare: The Next Five Years; COMPASS Pathways shares update from Phase IIb clinical trial; Will the magic of psychedelics transform psychiatry?
Will the UK be the first European country to embrace psilocybin-assisted therapy?; COMPASS shares COMP360 open-label study data; Where the psychedelic revolution is headed.
Will the UK be the first European country to embrace psilocybin-assisted therapy?; COMPASS shares COMP360 open-label study data; Where the psychedelic revolution is headed.
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Subscribe to the Psychedelics Newsletter
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.